Healthcare Industry News: Millennium
News Release - April 13, 2015
Takeda Announces Appointment of New President of U.S. Business UnitDEERFIELD, Ill., April 13, 2015 -- (Healthcare Sales & Marketing Network) -- Takeda Pharmaceutical Company Limited ("Takeda"), and Takeda's wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA") announced today that Ramona Sequeira will join TPUSA as President of the United States (U.S.) Business Unit. In this role, Sequeira will lead all business operations for the U.S., and will report to Christophe Weber, the President & Chief Executive Officer of Takeda.
"The U.S. is a critical market for Takeda's future growth, and I am confident that with her strong commercial experience and knowledge of the U.S. healthcare environment, Ramona is the right person to lead this important business unit and play a key role on my leadership team," said Weber. "Her more than 20 years of leadership experience and track record of success across multiple healthcare markets, as well as her demonstrated passion for patient centricity, will serve as a critical foundation during Takeda's global transformation."
Sequeira brings extensive leadership experience across multiple therapy areas including neuroscience, specialty and primary care, and several regions including the U.S., Canada and UK. Her most recent role was as Vice President, Lilly USA at Eli Lilly and Company. Previous to that, she was the General Manager of Lilly's UK Hub. Sequeira joins Takeda with a reputation and passion for driving external and internal excellence, from building brands and driving profitable growth, to cultivating high-performing teams.
Sequeira received an Honors Bachelor of Science in Molecular Biology and Molecular Genetics from the University of Toronto, and also earned a MBA from McMaster University in Hamilton, Ontario. She will assume the role as TPUSA president on June 1. She will be relocating from her current home in Indianapolis, IN to Deerfield, IL.
About Takeda Pharmaceuticals U.S.A., Inc.
Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine.
The company has a commercial presence covering around 70 countries, with particular strength in Asia, North America, Europe and fast-growing emerging markets including Latin America, Russia-CIS and China. Takeda is ranked 15th globally. Areas of focus include cardiovascular and metabolic, oncology, respiratory and immunology, central nervous system, general medicine, and vaccines.
Through the integration of Millennium Pharmaceuticals and Nycomed, Takeda has been transforming itself, broadening its therapeutic expertise and geographic outreach.
Takeda Pharmaceuticals U.S.A., Inc. is located in Deerfield, Ill., and is the U.S. marketing and sales organization of Takeda Pharmaceutical Company Limited.
Additional information about Takeda is available through its corporate website, www.takeda.com, and additional information about Takeda Pharmaceuticals U.S.A., Inc. is available through its website, www.takeda.us.
This press release contains forward-looking statements. Forward-looking statements include statements regarding Takeda's plans, outlook, strategies, results for the future, and other statements that are not descriptions of historical facts. Forward-looking statements may be identified by the use of forward-looking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "assume," "continue," "seek," "pro forma," "potential," "target," "forecast," "guidance," "outlook" or "intend" or other similar words or expressions of the negative thereof. Forward-looking statements are based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict. Investors are cautioned not to unduly rely on such forward-looking statements.
Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Some of these risks and uncertainties include, but are not limited to, (1) the economic circumstances surrounding Takeda's business, including general economic conditions in Japan, the United States and worldwide; (2) competitive pressures and developments; (3) applicable laws and regulations; (4) the success or failure of product development programs; (5) actions of regulatory authorities and the timing thereof; (6) changes in exchange rates; (7) claims or concerns regarding the safety or efficacy of marketed products or product candidates in development; and (8) integration activities with acquired companies.
The forward-looking statements contained in this press release speak only as of the date of this press release, and Takeda undertakes no obligation to revise or update any forward-looking statements to reflect new information, future events or circumstances after the date of the forward-looking statement. If Takeda does update or correct one or more of these statements, investors and others should not conclude that Takeda will make additional updates or corrections.
Source: Takeda Pharmaceutical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.